Ordentlich Peter 4

4 · Syndax Pharmaceuticals Inc · Filed Dec 2, 2022

Form 4

Period: 2022-12-01

Chief Technology Officer

Transactions

Exercise/Conversion
Common Stock
2022-12-02$6.38/sh+17,200$109,736→ 17,465 total
Exercise/Conversion
Common Stock
2022-12-01$6.35/sh+3,772$23,952→ 4,037 total
Exercise/Conversion
Common Stock
2022-12-01$6.38/sh+4,028$25,699→ 4,293 total
Sale
Common Stock
2022-12-01$25.01/sh−4,028$100,746→ 265 total
Exercise/Conversion
Stock Options (Right to buy)
2022-12-01−4,028→ 0 total
Exercise: $6.38Exp: 2029-02-06→ Common Stock (4,028 underlying)
Exercise/Conversion
Stock Options (Right to buy)
2022-12-02−17,200→ 0 total
Exercise: $6.38Exp: 2029-02-06→ Common Stock (17,200 underlying)
Sale
Common Stock
2022-12-01$25.01/sh−3,772$94,343→ 265 total
Sale
Common Stock
2022-12-02$25.05/sh−17,200$430,936→ 265 total
Exercise/Conversion
Stock Options (Right to buy)
2022-12-01−3,772→ 0 total
Exercise: $6.35Exp: 2024-12-18→ Common Stock (3,772 underlying)

Footnotes (4)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested.
[F2]The sale prices ranged from $25.00 to $25.03.
[F3]The sale prices ranged from $25.00 to $25.19.
[F4]This option is fully vested.

Documents

1 file